Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) questionnaire by Yahiaoui-Doktor, Maryam
  
 
Validation of the German version of the 
Mediterranean Diet Adherence Screener 
(MEDAS) questionnaire 
 
 
Dissertation 
to obtain the academic grade 
Dr. rer. med. 
 
at the Medical Faculty 
of the University of Leipzig 
 
 
Submitted by:  
Master of Science Maryam Yahiaoui-Doktor, née: Yahiaoui 
born on 25th April 1974 in Tehran, Iran 
 
Completed at:  
Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig 
 
Supervisor:  
Priv.-Doz. Dr. med. habil. Christoph Engel 
 
Decision on the award of the doctorate on:   
  
20.08.2019
  
 
 
 iii 
 
Bibliographical description 
Yahiaoui-Doktor, Maryam 
Validation of the German version of the Mediterranean Diet Adherence Screener (MEDAS) 
questionnaire 
University of Leipzig, Dissertation 
53 pages, 101 references (31 in publication1), 2 figures (1 in publication), 6 tables (5 in 
publication) 
Dissertation: 
Breast cancer is worldwide the most common cancer amongst women with 5-10% estimated to 
be inheritable. For women with germline pathogenic variants in BRCA1 and BRCA2 genes, the 
lifetime risk of developing breast and ovarian cancer is higher than the general population (69-
72% and 17-44%). Current options for women facing this risk are prophylactic surgery or 
intensive surveillance programmes. 
Prospective studies have shown physical activity and healthy nutrition can reduce the risk of 
sporadic breast cancer. Therefore, a randomised clinical trial (LIBRE) was initiated to evaluate 
whether a lifestyle intervention in carriers of BRCA1 and BRCA2 mutations could lead to a 
decrease in incidence and mortality rates for breast cancer. The intervention consists of physical 
endurance training and the adoption of the Mediterranean Diet (MD).  
The aim of the work presented in this thesis was to validate the German MEDAS. MEDAS was 
originally used in the Prevención con Dieta Mediterránea trial, in Spanish (published in 
English). It was translated from English into German for the LIBRE trial. For the validation, 
MEDAS was compared to the validated German Food Frequency Questionnaire (FFQ) and its 
associations with dietary intake biomarkers in the blood typical of the MD were analysed. 
MEDAS was more sensitive than FFQ in detecting adherence to the MD, while item level 
agreement varied. Associations were seen between MEDAS questions and corresponding 
dietary intake biomarkers in the blood. The strongest association was between fish consumption 
and the fatty acids omega-3 and omega-6. It was concluded MEDAS could be useful for 
assessing the adherence to the MD in clinical practice or trials.  
                                                 
1 Some references may occur in both the thesis and the publication. 
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1. Background 
 
Breast cancer is worldwide the most common cancer amongst females, affecting over 1.5 
million women each year, and it is the first cause of cancer-related death among women (1). 
The situation is similar in Germany where 69,220 women were diagnosed with this disease in 
2014 alone, while 18,136 died of it in 2015 (2). An estimated 5 to 10% of breast cancer 
incidences are hereditary, with a number of genes involved (3-5). 
Inheriting a pathogenic variant (mutation) of certain genes is known to increase the risk of 
developing breast cancer. The first of the responsible genes to be discovered, and the most 
widely known, are the breast cancer susceptibility genes Breast Cancer 1 and Breast Cancer 2 
(BRCA1 and BRCA2). They are both tumour suppressor genes, whose function is to control cell 
growth and repair damaged DNA. If both alleles of one of these genes themselves are defective, 
the gene cannot carry out its functions correctly, thus increasing the risk of tumour 
development, especially in the breast and ovaries in females. 
Inheriting one defective copy means the person is predisposed to disease development, i.e. with 
just one further variation, the gene’s functionality is lost. It has been shown that women who 
have inherited a pathogenic variant in one of these two genes have a higher lifetime risk of 
developing breast cancer. The cumulative risk of breast cancer to age 80 for mutation carriers 
was found to be 72% for BRCA1 and 69% for BRCA2, and 44% and 17% for ovarian cancer, 
respectively (6). 
Current options for these women are prophylactic surgery and intensive surveillance 
programmes. Prophylactic mastectomies almost eliminate the risk of developing breast cancer, 
while prophylactic bilateral salpingo-ophorectomy are thought to considerably reduce the risk 
of breast cancer and almost eliminate the risk of ovarian cancer in BRCA germline mutation 
carriers (7). This option however weighs heavily on those affected, as these are major 
irreversible operations with their own associated additional health risks (8, 9). As an alternative, 
intensive surveillance or breast cancer screening programmes allow regular monitoring of the 
health status of women at high risk, making early therapy and recovery possible. This option 
has its own drawbacks in that it can incur more costs and stress than is necessary for the women, 
healthcare providers and other stakeholders (10). 
Additionally, there are non-genetic (environmental or lifestyle) risk-modulating factors that 
play a role in disease development. In order to identify these, one can look to risk factors 
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identified in sporadic breast cancer studies. The effect of such factors on BRCA1 or BRCA2 
germline mutation carriers may then be determined through further studies. 
 
1.1. Lifestyle factors and risk of sporadic breast cancer 
 
Physical activity, nutrition and weight, regardless of age have been found to be amongst factors 
affecting the risk of sporadic breast cancer development (11, 12). It is estimated that the lifetime 
breast cancer risk in all women could be reduced by 30% through lifestyle measures such as 
weight control, exercise and moderating alcohol intake (13). Energy intake restriction and 
weight control (through diet regimen) have shown clearer effects on risk reduction, whereas the 
effects of specific dietary components have been more difficult to quantify (13). In short, 
exercise, nutrition and weight control are three related lifestyle factors combining to affect 
breast cancer risk. 
Significant reduction of breast cancer incidence in both pre- and post-menopausal women 
through regular exercise has been shown in many prospective studies, reducing the risk on by 
25% average (14). The risk of a relapse and mortality due to breast cancer have been shown to 
be reduced by around 24-40% for women who exercise more and regularly (15). Additionally, 
with more and regular exercise, breast cancer patients are likely to benefit from an enhanced 
quality of life, higher fitness levels and better tolerance of chemotherapy and its associated side 
effects (16-19). 
The risk of breast cancer is increased significantly due to weight gain and obesity in both pre- 
and postmenopausal women (20, 21). Overall, up to 15% of sporadic breast cancer cases could 
be due to a weight gain of 2 kg or more from the age of 18 years onwards, and approximately 
4.4% because of a weight gain of 2 kg or more following the onset of menopause (20). 
As well as increasing the risk for primary tumour development, obesity is a predictive factor 
for both developing distant metastases (46% risk increase for BMI over 30) and mortality (38% 
risk increase for BMI over 30) as a result of breast cancer (22). There is also indication that 
BMI affects the effectiveness of breast cancer therapy, both chemo- and endocrine therapy 
having been less effective after 10 or more years for patients with BMIs greater than 30 (22). 
This trend has been found elsewhere; obesity in particular increases the risk of disease, one 
review of 82 studies on the topic finding poorer breast cancer survival results in association 
with obesity irrespective of age (23-26). 
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Weight gain results in shifting levels of insulin, glucose and fats in the body, which allow 
tumours to develop and progress, the complex biological mechanisms and pathways of which 
are not yet fully identified (27). To this end, several trials have explored the effects of particular 
diets and dietary components on the risk of breast cancer. 
Compared with a usual diet group, a low-fat dietary pattern was found to lead to a lower 
incidence of deaths in breast cancer survivors (28). Another study found a ‘prudent’ diet – 
characterised by higher consumption frequency of dairy products, fruit and vegetables, 
wholemeal bread, fish and juices – was associated with lower risk for breast and lung cancer 
compared to fast-food or old traditional Polish diets (29). Elsewhere, a ‘healthy’ diet was among 
items of healthy behaviour, which reduced the risk of various cancers, including that of the 
breast (30). Consuming more vegetables and fruit was associated with decreased breast cancer 
risk in another recent study (31). Grilled meat and higher cholesterol intake on the other hand 
were found to increase breast cancer risk (32). 
There are other lifestyle factors associated with breast cancer, although the focus of this work 
is diet. Alcohol consumption is one of these, here the general view is that avoiding 
overconsumption would be advantageous in reducing breast cancer risk (33). Tobacco 
consumption particularly increases the risk of disease in the years between menarche and the 
first full time pregnancy (24, 25). Managing and reducing stress are factors that also play a role, 
for instance cognitive behavioural intervention to manage stress could help increase 
immunologic resistance by regulating cortisol levels (34). 
 
1.2. Mediterranean Diet 
 
Willett et al. described “a food pyramid that reflects Mediterranean dietary traditions, which 
historically have been associated with good health” (35). This diet is characterised by plentiful 
consumption of plant foods; moderate amounts of dairy products, fish, poultry and eggs; and 
low amounts of red meat. Olive oil is the principal source of fat, while desserts are based on 
fruits, and wine may be consumed with meals in low to moderate amounts. 
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Figure 1 - The Mediterranean Diet pyramid - Courtesy of Oldways, oldwayspt.org 
 
This nutritional base, combined with physical activity, is seen to have led to longer life 
expectancy and lower rates of several diseases, including some cancers, especially in Greece 
and southern Italy in the early 1960s. Elsewhere in the world, dietary patterns sharing the 
common characteristics of what has been defined as Mediterranean have been associated with 
better life expectancy and lower chronic diseases rates (36). Figure 1 illustrates the 
Mediterranean Diet (MD) alongside physical activity.  
Some studies have looked into the association between the adherence to this dietary pattern and 
sporadic breast cancer risk. There are indications that the MD acts as a protective factor against 
breast cancer. For instance, pooled analyses of individual components of the MD found that its 
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protective effects appear to be most attributable to fruits, vegetables, and whole grains (37). 
The antioxidants and anti-inflammatory properties of the food items in the MD might explain 
its benefits against the development of many diseases including cancer, was the conclusion of 
another study (38). An increased risk of breast cancer was seen in women who consumed a pro-
inflammatory diet, especially in postmenopausal years (39, 40). 
The MD or a diet close to it – rich in fruits, vegetables, legumes, oily fish and vegetable oils – 
seem to be advantageous in the effort to reduce breast cancer risk (41-43). The biological 
mechanisms for cancer prevention or risk reduction associated with the MD have been linked 
to the favourable effect of a balanced ratio of omega-6 and omega-3 fatty acids and high 
amounts of fibre, antioxidants and polyphenols found in fruit, vegetables, olive oil and wine 
(44). 
A review in 2015 concluded there to be insufficient data to reach a final conclusion about the 
effect of the MD on breast cancer risk in pre- and postmenopausal women, but that there was 
evidence suggesting the effect is protective (45). Often in the studies the level of adherence to 
the MD is quantified by a score (the MD score), which sums up the number of MD items or 
food groups consumed on a regular basis. A recent systematic review (2018) found results from 
analysing the effects of the MD on breast cancer risk using different versions of MD scores to 
be consistent, and suggest an inverse relationship with Oestrogen receptor-negative breast 
cancer (46). There have also been attempts to quantify the effect of the MD on changes in the 
risk of breast cancer development in some studies. The results were in accordance with the trend 
seen previously, showing a protective association between the MD with regards to breast cancer 
risk, with a risk reduction of up to 6% (37, 47-49). 
 
1.3. Non-genetic risk factors for disease in BRCA1 and BRCA2 mutation carriers 
 
As discussed, several factors are involved in the development of sporadic breast cancer. These 
include environmental and lifestyle factors, material exposure (e.g. chemicals, radiation, 
metals, etc.), activity, diet, alcohol and tobacco (50). Inferring from risk factors for sporadic 
breast cancer, it may be possible to undertake measures to reduce the risk of breast cancer 
development for women with germline pathogenic variants of BRCA1 and BRCA2. 
Previously, aspects such as the number of pregnancies, the year of birth, physical activity in 
youth, as well as breast feeding were found to affect the risk of disease development in BRCA1 
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and BRCA2 mutation carriers (51-53). Additionally, BMI or height at different ages were seen 
to affect the risk of disease development in this population, just as for sporadic breast cancer 
patients (54, 55). Menopausal status modifies the association between body weight and breast 
cancer development risk in this population (56). It was also found that physical activity or 
exercise directly affects oestrogen levels and hormonally sensitive breast tissue, which can in 
turn influence the risk of disease development in BRCA1 and BRCA2 mutation carriers (57). 
Controlling adult weight through diet is an important factor in the prevention of BRCA related 
breast cancer (58). Until now, a few studies have investigated the relationship between disease 
onset and particular food items in carriers of germline BRCA1 and BRCA2 mutations. For 
instance, it was concluded that consumption of vegetables and fruit might help reduce the risk 
of breast cancer in BRCA mutation carriers, while higher total energy intake, and coffee and 
alcohol consumption can increase this risk (59, 60). Soya consumption for instance, may reduce 
the risk of disease development in this population (61). 
The effect of the MD on the risk of breast cancer has however thus far been investigated in very 
few studies in carriers of germline pathogenic variants of BRCA1 and BRCA2. Bruno et al. have 
reported the initial results of their trial, which examines effects of the MD and physical activity 
in this population. The intervention group showed an improvement in their MD scores and 
Metabolic Syndrome (62). 
Given the need for further research in this area, a clinical trial was designed and initiated for 
this group of women to understand better the viability of regular exercise and diet improvements 
as possible breast cancer prevention measures. This is the Lifestyle Intervention Study in 
Women with Hereditary Breast and Ovarian Cancer (LIBRE) trial. 
 
1.4. LIBRE trial 
 
LIBRE is a prospective, open-label, randomised (1:1), controlled and multi-centre clinical trial, 
carried out in two phases (63). Its participants are women with a germline pathogenic variant 
in the BRCA1 or BRCA2 gene. The primary aim of LIBRE-1 has been to evaluate the feasibility 
of the design of the study, including the intervention method. A total of 68 participants were 
recruited in three centres of the German Consortium for Hereditary Breast and Ovarian Cancer 
(Cologne, Kiel and Munich) starting in 2014. This phase of the trial is currently in its follow-
up stages, having been confirmed as feasible allowing the larger LIBRE-2 phase to ensue. 
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LIBRE-2 aims to recruit at least 600 participants and study as its primary endpoints the 
adherence to the MD, BMI and ventilatory threshold VT1 after one year of intervention (64). 
There are several secondary endpoints of the LIBRE-2 trial, some of which are: measurements 
on quality life, stress coping, fat calorie intake, physical activity and body fat content. 
The intervention in the LIBRE study comprises a one-year endurance exercise programme 
combined with the adoption of the MD. The exercise part consists of home- and centre-based 
training, while the nutritional part includes courses and supermarket shopping trips on 
components of the MD. The intervention is divided into two parts, an intensive phase (the first 
three months) during which contact with participants is on a weekly basis and a light phase (the 
following nine months) when there is only telephone contact with participants every three 
months. The control group receive recommendations on a healthier lifestyle, including general 
advice on the importance of exercise and nutrition once. The nutritional advice is in accordance 
with the recommendations of the German Society of Nutrition. 
Two food intake questionnaires – the Mediterranean Diet Adherence Screener (MEDAS) and 
the Food Frequency Questionnaire (FFQ) from the European Prospective Investigation into 
Cancer and Nutrition (EPIC) – are given to both the intervention and control groups. Both 
questionnaires are used to determine the dietary habits of the LIBRE participants and are 
described in more detail in the next two sections. They are given to the participants at Baseline, 
three months and then twelve months for both groups; plus at each yearly follow-up afterwards 
for up to 3 years. In LIBRE-1, the intervention group additionally answered MEDAS at six and 
nine months. The focus of this dissertation is on the intensive phase of the intervention, i.e. 
between the time of start of the intervention and three months later. 
 
1.5. Mediterranean Diet Adherence Screener questionnaire 
 
This is a questionnaire originally used in the Prevención con Dieta Mediterránea (PREDIMED) 
trial, in the Spanish language (65). Schröder et al. validated this original version of the MEDAS, 
which they published in the English language (66). For the LIBRE-1 study, MEDAS was 
translated from the English version into German using a method describe in detail in the next 
section. The usage context of the questionnaire was a short and rapid screener, for clinical 
practice, to determine the adherence to the pre-defined Mediterranean Diet as described by 
Willett et al. (35, 66). 
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The MEDAS questionnaire consists of 14 questions, which typify the MD. Each answer that 
matches the MD gets one point to build a total (sum) MD score of up to 14. Table 1 below lists 
the English questions and their point distributions. 
 
Table 1- MEDAS questions in English 
Question +1 point 0 point 
1. Do you use olive oil as the principal source of fat for 
cooking? 
Yes No 
2. How much olive oil do you consume per day (including that 
used in frying, salads, meals eaten away from home, etc.)? 
At least 4 
tablespoons 
Less than 4 
tablespoons 
3. How many servings of vegetables do you consume per day?  At least 2 Less than 2 
4. How many pieces of fruit (including fresh-squeezed juice) 
do you consume per day? 
At least 3 Less than 3 
5. How many servings of red meat, hamburger, or sausages do 
you consume per day? 
Less than 1 At least 1 
6. How many servings (12 g) of butter, margarine, or cream do 
you consume per day? 
Less than 1 At least 1 
7. How many carbonated and/or sugar-sweetened beverages 
do you consume per day? 
Less than 1 At least 1 
8. Do you drink wine? How much do you consume per week? At least 
seven cups 
Less than 
seven cups 
9. How many servings of pulses do you consume per week? At least 3 Less than 3 
10. How many servings of fish/seafood do you consume per 
week? 
At least 3 Less than 3 
11. How many times do you consume commercial (not 
homemade) pastry such as cookies or cake per week? 
Less than 2 At least 2 
12. How many times do you consume nuts per week? At least 3 Less than 3 
13. Do you prefer to eat chicken, turkey or rabbit instead of 
beef, pork, hamburgers, or sausages? 
Yes No 
14. How many times per week do you consume boiled 
vegetables, pasta, rice, or other dishes with a sauce of 
tomato, garlic, onion, or leeks sautéed in olive oil? 
At least 3 Less than 3 
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For the LIBRE-1 and 2 trials, MEDAS was complemented with pictures of foods that matched 
the questions, which is appended to this thesis. 
 
1.5.1. Translation process 
 
This translation was carried out by members of the project team as part of LIBRE-1, and 
followed the guidelines from the International Society of Pharmacoeconomics and Outcomes 
Research (67). The MEDAS was translated from its validated version (in English) into German, 
and then two native German speakers reviewed it. An English native speaker then translated 
this reviewed version back into English. A group of the study team then approved the back-
translated version by comparing it to the original English version. 
 
1.6. Food Frequency Questionnaire 
 
This was the larger nutritional questionnaire used in the LIBRE trial, and was the questionnaire 
that MEDAS was compared to as part of the validation process. The FFQ was developed within 
the framework of the EPIC study. The FFQ (German version used in LIBRE) is a detailed 33 
page, 148 item questionnaire on food habits twelve months prior to being administered (68-70). 
It asks about general nutritional behaviour, before going into specific details on nutritional 
supplements and then portions and frequency of solid and liquid food groups’ intake. The food 
groups comprise bread and cereals, milk and dairy products, fruit, raw vegetables, meat and 
fish to name but a few. Colour photos accompany items that are not consumed in normal 
household quantities to make understanding the portions easier. There are also specific 
questions on the type of cooking fats used, the frequency of consumption of sauces with fish or 
meat, the fat content of consumed milk products, the use of sugar and milk in coffee or tea and 
the seasonal consumption of fresh fruit and vegetables. At the end, a summary regarding food 
intake in summer and winter, plus weight and height of the participant is asked. 
The German Institute of Human Nutrition (Deutsches Institut für Ernährungsforschung - DifE) 
administers and analyses data gathered from this questionnaire. The resulting dataset contains 
all answers from which, for the MEDAS validation, the relevant items were chosen. 
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2. Aim 
 
The aim of the work presented in this thesis was to determine the suitability of the German 
version of MEDAS as a short and practical questionnaire for everyday clinical use to determine 
the level of adherence to the MD. In order to do this, MEDAS was compared to the larger, 
validated FFQ, which measures food intake in general. 
Several measures of concordance were used to analyse item-level agreement between the 14 
MEDAS questions and corresponding items from FFQ. These were the absolute agreement, 
Pearson’s product-moment correlation, Cohen’s kappa and intraclass correlation. 
In order to see how the questionnaire scored the MD compared to one another, the Bland-
Altman method was used. Subsequently, t-Test and multivariate regression analyses were used 
to explore whether MEDAS could specifically determine the adherence to the MD. In this step, 
β-carotene, fatty acids omega-3, omega-6 and omega-9, and high-sensitivity C-reactive protein 
(hs-CRP) were analysed for their associations with MEDAS questions regarding vegetables and 
fruits, olive oil, red meat, fish and nuts. 
These analyses were carried out for the two time points Baseline and after three months. The 
results are presented in the following publication. 
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Background
The MD has been tested for its health benefits in different
at-risk populations with favourable results. For instance,
randomized controlled intervention studies revealed that
MD is effective in the primary prevention of cardiovascu-
lar diseases [1, 2], in lowering hypertension and athero-
genic lipoproteins [3, 4] and in improving diabetes [5].
More recently, studies in the older population showed an
association between MD and improved cognitive function
[6]. Epidemiological studies from the European Prospect-
ive Investigation into Cancer and Nutrition (EPIC) cohort
suggested further that MD might protect against cancer,
especially gastric cancer [7], colorectal cancer [8] and
bladder cancer [9].
Such trials raised the need for a useful tool to assess
MD adherence in study populations. The PREDIMED
consortium established a 14-point MEDAS questionnaire,
which was validated by administering the established FFQ
[10] and MEDAS to 7146 participants from the PRE-
DIMED study. The authors found that the average
MEDAS score estimate was 105% of the FFQ PREDIMED
score estimate, and thus is a valid instrument for rapid es-
timation of adherence to the MD [11]. Moreover, the PRE-
DIMED investigators could show that MEDAS is able to
capture a strong monotonic inverse association between
adherence to MD and obesity indices in a population of
adults with a high cardiovascular risk [12].
In Germany, a multicentre trial, the ‘Lifestyle interven-
tion in BRCA 1/2-mutation carriers’ (LIBRE) was launched
to investigate the effect of a defined lifestyle intervention
on breast cancer incidence in women at high genetic risk
for this type of cancer [13]. Up to 60% of women with
BRCA mutations develop breast or ovarian cancer [14],
but not all of them, suggesting that environmental co-
factors play a role. Indeed, some studies suggested that
physical activity and dietetic intervention help prevent
cancer, including breast cancer [15, 16]. To test the
hypothesis of whether these controllable environmental
factors further modulate cancer risk, the LIBRE trial con-
ducts an intervention with clearly defined sport and nutri-
tion components. The nutritional component of the
intervention was based on the MD. The German transla-
tion of MEDAS was used as an instrument to assess adher-
ence. The purpose of the present study was to validate the
German version of MEDAS.
Methods
Study population
The LIBRE study is divided into two parts: firstly, a feasi-
bility study to prove the practicability of the lifestyle inter-
vention and consequently, the presently recruiting main
trial with the aim of attaining 600 study participants to
demonstrate the effects of the lifestyle intervention on the
breast cancer incidence in women with BRCA1 or BRCA2
genetic mutations. 68 women, who were all participants of
the LIBRE feasibility study, formed the study population
for these analyses. The details of the trial have been pub-
lished elsewhere [13]. The study population (adult women
between 18 and 75 years) was recruited from February
2014 to July 2014 in selected consultation centres of the
German Consortium of Hereditary Breast and Ovarian
Cancer in Kiel, Cologne and Munich. All participants
signed an informed written consent. The trial was ap-
proved by the responsible ethical committees.
Study participants were randomized into two groups
with a ratio of 1:1, stratified by participating centre and
previous breast cancer. The intervention group (IG)
(n = 35) received a detailed lifestyle intervention over
12 months, and the control group (CG) (n = 33) re-
ceived no intervention, but standard recommendations
for a healthier lifestyle. The lifestyle IG received a super-
vised physical exercise training program and nutritional
education based on the MD. In the first 3 months, the
nutritional education took place every fortnight, there-
after at monthly intervals. The CG received minimal nu-
tritional education based on the recommendations of
the German Society of Nutrition (DGE - https://
www.dge.de/en/) “Usual Care in Germany“and some
general advice for increasing activity in everyday life at
the beginning of the study (one session). All participants
were asked to fill out both a full-length FFQ and
MEDAS at study start (baseline) and 3 months later. We
chose both time points to prove whether MEDAS is spe-
cific enough by measuring MD-typical changes during
the intervention. Only data collected within this period
were used for the purposes of the current study. Solely
participants who had completed both questionnaires
were included in the analysis. These were in total 66 par-
ticipants at baseline (34 in the IG and 32 in the CG) and
54 at month three (27 in the IG and 27 in the CG).
We used the guidelines from the International Society
for Pharmacoeconomics and Outcomes Research (ISPOR)
to guide our translation process [17]. MEDAS from the
English PREDIMED-publication [11] was translated into
German and reviewed by two native speakers in German.
It was then translated back into English by a native
speaker. Following this, the final version was read and ap-
proved in a small group of the study team.
Dietary assessment
MEDAS is a 14-item screener, which consists of 12
questions on food consumption frequency and 2 ques-
tions on food intake habits characteristic of the MD
(Table 1). Each question was scored with a 0 or 1. One
point was given for using olive oil as the principal source
of fat for cooking and one for preferring white meat over
red meat, and one for consuming each of the following:
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! 4 or more tablespoons (1 tablespoon = 13.5 g) of
olive oil/d (including that used in frying, salads,
meals eaten away from home, etc.);
! 2 or more servings of vegetables/d;
! 3 or more pieces of fruit/d;
! fewer than 1 serving of red meat or sausages/d;
! fewer than 1 serving of animal fat/d;
! fewer than 1 cup (1 cup =100 mL) of sugar-
sweetened beverages/d;
! 7 or more servings of red wine/wk.;
! 3 or more servings of pulses/wk.;
! 3 or more servings of fish/wk.;
! fewer than 3 commercial pastries/wk.;
! 3 or more servings of nuts/wk.; or
! 2 or more servings/wk. of a dish with a traditional
sauce of tomatoes, garlic, onion, or leeks sautéed in
olive oil.
If the condition was not met, 0 points were recorded for
the category. The MEDAS score (sum of above items)
ranged from 0 to 14 points [11].
All participants were also asked to complete a 148-
item semi-quantitative FFQ. The German version had
been validated by the German EPIC investigators [18–21].
For each item it questions the average serving size, de-
scribed by photos, and the food frequency during the
previous 12 months. Furthermore, it contains questions
on cooking oil, frequency of the use of gravy, the fat
content of dairy products, the use of sugar and milk in
coffee and tea, and the seasonal consumption of fruit
and vegetables. The documentation of the question-
naire was done via the study-management-system for
Epidemiology and Public Health, which was developed
and supervised by the Department of Epidemiology of
the German Institute of Human Nutrition Potsdam-
Rehbruecke.
Food intake data recorded by FFQ was grouped into
the food-based dietary components of MEDAS (Table 1).
We validated the dietary assessment data retrieved from
MEDAS by comparing it with the data gathered from
the validated FFQ and confirmed this by associating with
the results from the blood tests.
Table 1 MEDAS questions and transfer of food intake data from FFQ into its food groups
MEDAS question data recorded by FFQ
1. Do you use olive oil as the principal source of fat for cooking? 1 point given: use of olive oil for the preparation of at least 2 of the
following groceries: salad, vegetable, meat/fish (FFQ Question: Pages
14 and 19)
2. How much olive oil do you consume per day (including that used
in frying, salads, meals eaten away from home, etc.)?
1 point given: based on FFQ calculation, if >48 g vegetable oil
3. How many servings of vegetables do you consume per day? 1 point given: based on FFQ calculation, if ≥2 portions of vegetables per
day (including salad, olives, mushrooms)
4. How many pieces of fruit (including fresh-squeezed juice) do you
consume per day?
1 point given: based on FFQ calculation, if ≥3 portions of fruit (including
mixed fruit, mixed stewed fruit and fruit juices)
5. How many servings of red meat, hamburger, or sausages do you
consume per day?
1 point given: based on FFQ calculation, if <100 g meat (beef, veal, pork,
lamb) and processed meat products
6. How many servings (12 g) of butter, margarine, or cream do you
consume per day?
1 point given: based on FFQ calculation, if <1 portion butter, margarine
and cream
7. How many carbonated and/or sugar-sweetened beverages do you
consume per day?
1 point given: based on FFQ calculation, sugar-sweetened beverages <1
portion per day (including lemonade and colas)
8. Do you drink wine? How much do you consume per week? 1 point given: based on FFQ calculation, if ≥7 portions wine (red
and white)
9. How many servings of pulses do you consume per week? 1 point given: ≥ 3 portions pulses per week (page 14)
10. How many servings of fish/seafood do you consume per week? 1 point given: based on FFQ calculation, if ≥3 portions fish, fish products
and seafood per week
11. How many times do you consume commercial (not homemade)
pastry such as cookies or cake per week?
1 point given: based on FFQ calculation, if <3 portions cakes, chocolate,
cookies, sweets with and without chocolate per week
12. How many times do you consume nuts per week? 1 point given: based on FFQ calculation, if ≥3 portions nuts and seeds
per week (page 11)
13. Do you prefer to eat chicken, turkey or rabbit instead of beef, pork,
hamburgers, or sausages?
1 point given: based on FFQ calculation, if g white meat (poultry,
chicken, rabbit) > g red meat (beef, veal, pork, lamb, processed
meat products)
14. How many times per week do you consume boiled vegetables, pasta,
rice, or other dishes with a sauce of tomato, garlic, onion, or leeks
sautéed in olive oil?
1 point given: > 1–2 times a week tomato sauce (page 21)
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Measurement of dietary intake biomarkers in the blood
To confirm whether MEDAS’ tendency towards the MD
is consistent, we selected specific biomarkers in the blood
which are described in the literature to be associated with
consumption of certain MD food components [1, 22, 23].
Blood samples were taken at the same time points as
the completion of both questionnaires (baseline and
after 3 month). Following 30 to 60 min of incubation the
serum was centrifuged at 3000*g for 10 min in the
consultation centres and was overnight delivered chilled
together with the EDTA (ethylene diamine tetraacetic
acid) blood samples to the central laboratory at the Uni-
versity of Hohenheim.
A part of the serum was passed directly to an external la-
boratory (Medizinisches Labor Bremen, Bremen, Germany)
to measure β-carotene by high performance liquid chroma-
tography (HPLC). The rest of the serum aliquots were
stored at −80 °C in Hohenheim until the measurement of
hsCRP using a sandwich Enzyme Immuno Assay (K 9710S,
Immundiagnostik AG, Bensheim, Germany) was done. The
erythrocyte membrane was isolated from the EDTA blood
and also stored at −80 °C in Hohenheim until the fatty acid
profile (omega-6-, omega-3- and omega-9-fatty acids) was
analyzed after acid esterification using gas chromatography/
mass spectrometry by the Institute of Food Chemistry of
the University of Hohenheim [24, 25].
Statistical analysis
Patient characteristics were analyzed descriptively, split by
study arm. For age and Body Mass Index (BMI), a t-Test
was used to determine whether the two groups were sta-
tistically different. For all other characteristics, coded as
binary items, a Chi2 test was used.
We then determined the concordance between the an-
swers to the MEDAS questionnaire compared to the
answers for corresponding questions in the FFQ ques-
tionnaire both at Baseline and at 3 months. First, the
absolute agreement in percentage was calculated, which
was further investigated using Cohen’s kappa (κ) and the
intraclass correlation coefficient (ICC). The relative
agreement between the corresponding items was exam-
ined using the Pearson product–moment correlation.
The agreement between the sum from the MEDAS
questionnaire and the equivalent FFQ questions was ex-
amined using a Bland-Altman analysis. The mean of the
two values was plotted on the x-axis and the difference
on the y-axis, in order to determine possible bias. The
95% limits of agreement lines, defined as the mean dif-
ference ± 1.96 times the standard deviation of the differ-
ences, were also plotted. A linear regression was then
carried out with the difference as the dependent value,
whose line was added to the plot with its corresponding
formula and p-value.
In a further step, we validated whether the MEDAS
questionnaire can specifically determine adherence to a
MD, the association of blood values for β-carotene, the
fatty acids omega-3, omega-6 and omega-9 and hsCRP,
and MEDAS items (β-carotene associated with the
MEDAS item regarding vegetables and fruits; hsCRP,
omega-3 fatty acids, omega-6 fatty acids and omega-9 fatty
acids associated with the MEDAS item regarding olive oil;
omega-3 fatty acids and omega-6 fatty acids associated
with the MEDAS item regarding red meat, fish and nuts).
We first applied a t-Test for independent groups (control
or intervention) for each of the food items and each of the
dietary biomarker values, carried out separately for each
of the two time points. Following this, we carried out a
multivariate linear regression on the associations de-
scribed above, where we also adjusted for the study arm.
The statistical analysis was done using R (program for
statistical computing) in the R Studio environment Version
0.99.902.
Results
Patient characteristics
Patient characteristics at baseline are outlined in Table 2.
The IG comprised 35 women at this point in time, while
the CG comprised 32. Considering attributes such as
BMI, age and history of breast cancer, these groups did
not differ statistically significantly from one another. Both
groups included a number of smokers (11% in the IG and
9% in the CG). A vegetarian diet was also followed by a
group of the study participants (6% in the IG and
13% in the CG).
Item by item agreement
The absolute and relative agreements between the FFQ
and the MEDAS questionnaires were calculated at base-
line and at 3 months for the whole sample (Table 3).
This concordance at Baseline was highest for questions
1: olive oil as principal source of fat (Pearson’s product–
moment correlation 0.70, κ 0.70 and an ICC of 0.68),
and 12: nuts (Pearson’s product–moment correlation
0.72, κ 0.70 and an ICC of 0.68). After 3 months the
highest concordance was obtained for questions 9:
pulses (Pearson’s product–moment correlation 0.86, κ
Table 2 Study patient characteristics at baseline (n = 67)
Intervention group (MD)
n = 34
Control group
N = 32
Age [years]a 42 (27–72) 42 (24–68)
BMI [kg per m2]a 23 (18–45) 23 (18–43)
History of breast cancerb 24 (71%) 21 (66%)
Smokerb 4 (11%) 3 (9%)
Vegetarianb 2 (6%) 4 (13%)
amedian (range)
bnumbers (percent)
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0.85 and an ICC of 0.91), and 12: nuts (Pearson’s prod-
uct–moment correlation 0.78, κ 0.77 and an ICC of
0.76). Questions 7: sugar-sweetened beverages at Base-
line and 2: daily olive oil had the lowest concordances
with negative values.
MEDAS total score agreement
The MEDAS score was analyzed using a Bland-Altman
plot (Fig. 1). The mean MEDAS scores were 15% higher
than the FFQ score at baseline and 23% higher after
3 months, with the median MEDAS score being higher
Table 3 Agreement between MEDAS and FFQ (German)
Question Baseline (n = 66) 3 months (n = 54)
r AA κ ICC r AA κ ICC
1 0.70 0.87 0.70 (0.51 to 0.89) 0.68 (0.07 to 1.3) 0.51 0.87 0.51 (0.22 to 0.81) 0.55 (−0.19 to 1.28)
2 0.29 0.86 0.23 (−0.07 to 0.53) 0.21 (−0.35 to 0.76) −0.09 0.70 −0.034 (−0.1 to 0.03) −0.03 (−0.08 to 0.02)
3 0.30 0.63 0.28 (0.06 to 0.49) 0.14 (−0.26 to 0.54) 0.25 0.62 0.19(−0.02 to 0.4) 0.15 (−0.36 to 0.66)
4 0.42 0.70 0.36 (0.15 to 0.56) 0.28 (−0.33 to 0.88) 0.08 0.25 0.087 (−0.16 to 0.31) −0.03 (−0.06 to 0.01)
5 0.58 0.81 0.50 (0.28 to 0.72) 0.52 (−0.20 to 1.24) 0.40 0.87 0.39 (0.03 to 0.75) 0.04 (−0.35 to 1.14)
6 0.45 0.73 0.45 (0.22 to 0.67) 0.32 (−0.33 to 0.97) 0.23 0.61 0.22 (−0.03 to 0.48) 0.06 (−0.20 to 0.33)
7 −0.04 0.91 −0.03 (−0.07 to 0.02) −0.11 (−0.14 to −0.08) n/a 0.96 n/a −0.33 (−0.38 to −0.28)
8 0.35 0.83 0.28 (−0.001 to 0.57) 0.51 (−0.28 to 1.30) 0.24 0.91 0.21 (−0.19 to 0.6) 0.37 (−0.57 to 1.31)
9 n/a 0.92 n/a n/a 0.86 0.96 0.85 (0.66 to 1.1) 0.91 (0.68 to 1.14)
10 0.25 0.84 0.21 (−0.18 to 0.61) 0.22 (−0.42 to 0.87) 0.28 0.74 0.21 (−0.04 to 0.45) 0.13 (−0.28 to 0.55)
11 0.44 0.77 0.37 (0.14 to 0.6) 0.33 (−0.33 to 0.99) 0.64 0.83 0.61 (0.39 to 0.83) 0.58 (−0.13 to 1.28)
12 0.72 0.86 0.70 (0.52 to 0.87) 0.68 (0.05 to 1.30) 0.78 0.89 0.77 (0.61 to 0.94) 0.76 (0.23 to 1.28)
13 0.18 0.43 0.06 (−0.01 to 0.13) 0.03 (−0.14 to 0.20) 0.13 0.27 0.03 (−0.01 to 0.08) 0.01 (−0.15 to 0.13)
14 0.39 0.69 0.38 (0.16 to 0.6) 0.25 (−0.33 to 0.83) 0.17 0.60 0.17 (−0.01 to 0.43) 0.02 (−0.14 to 0.18)
AA = absolute agreement, r = Pearson’s product–moment correlation, κ = Cohen’s Kappa with the confidence intervals in brackets, ICC = Intraclass Correlation
Coefficient with the confidence intervals in brackets
Fig. 1 Bland-Altman plots showing the differences between the MEDAS score aggregated from MEDAS and FFQ questionnaires at baseline and
after 3 months. The red dashed and dotted lines indicate the mean bias and its 95% confidence interval. The blue dashed and dotted lines depict
limits of agreement and their 95% confidence intervals
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than the FFQ equivalent by 1 point at baseline and 2
points after 3 months. This corresponds to a mean
difference of 1.27 at baseline and 2.12 after 3 months,
which defines the bias towards higher score sums being
obtained by the MEDAS questionnaire. Linear regression
analysis revealed a significant increase of the bias with
increasing score values (p < 0.001 for baseline, p < 0.001
after 3 months).
Measurement of dietary intake biomarkers in the blood
The possible association between laboratory measure-
ments and intake of particular food groups was first ana-
lyzed on a per item basis (Table 4). After the 3-month MD
intervention some of these associations showed a statis-
tical significance or near-significance. Consumption of at
least 3 portions of fish per week was associated with lower
omega-6 fatty acid levels (p = 0.035) and higher omega-3
fatty acid levels (p = 0.053). Consumption of at least 3 por-
tions of fruit per day was associated with higher levels of
β-carotene (p = 0.056). Consumption of at least 2 portions
of vegetables per day was associated with higher levels of
β-carotene (p = 0.004). We have depicted these associa-
tions in Fig. 2.
We also examined the same associations in a multi-
variate model, as reported in Table 5. Consumption of at
least three portions of fish per week showed increased
levels of omega-3 (p = 0.037) and decreased levels of
omega-6 fatty acid (p = 0.026) in the blood, both of
which were statistically significant.
Discussion
MEDAS was developed for the Spanish PREDIMED
study to expediently determine adherence to the MD
and allow an immediate feedback to the patient. This
short screener is a validated tool for the rapid assess-
ment of adherence to the MD [11], which is why it was
decided to use a German-translation of this question-
naire in the LIBRE study. However, the original MEDAS
was not in German. To validate the German translation
of this questionnaire, we used the validated German full-
length FFQ as reference.
In general agreement between FFQ and MEDAS ques-
tionnaires was of a fair or better level (0.4 and larger
values for agreement coefficients) for about half of the
MEDAS questions [22]. These differences are likely due
to the way FFQ is structured and to the fact that it is dif-
ferently analyzed. FFQ measures the food frequency of a
selected list of German foods with standardized portion
sizes for the previous 12 months. These answers are
then used to calculate intake for food groups while
MEDAS directly asks for the habits and consumption
frequency of specific amounts of specific Mediterranean
Table 4 MEDAS food groups association with dietary biomarkers in the blood
Baseline (n = 66) At 3 months(n = 54)
MEDAS food group association
with dietary biomarker(s)
Mean for group
with 0 point (n)
Mean for group
with 1 point (n)
p-value Mean for group
with 0 point (n)
Mean for group
with 1 point (n)
p-value*
vegetables with
β-carotene [μg/l] 859.7 (26) 889.3 (39) 0.868 487.8 (9) 918.91 (45) 0.004
fruit with
β-carotene [μg/l] 786.6 (36) 1009.51 (29) 0.183 689.5 (25) 984.181 (29) 0.056
how much olive oil with
hsCRP [mg/l] 0.6 (54) 0.51 (11) 0.337 0.7 (39) 0.51 (15) 0.218
omega 3 [%] 14.0 (54) 13.7 (11) 0.763 13.2 (39) 13.81 (15) 0.513
omega 6 [%] 27.5 (54) 27.3 (11) 0. 831 25.0 (39) 25.01 (15) 0.983
omega 9 [%] 14.08 (54) 13.77 (11) 0.185 15.4 (39) 15.16 (15) 0.362
red meat with
omega 3 [%] 14.2 (21) 13.8 (44) 0.665 12.1 (8) 13.3 (45) 0.202
omega 6 [%] 27.5 (21) 27.4 (44) 0.908 25.0 (8) 25.2 (45) 0.849
fish with
omega 3 [%] 14.1 (59) 12.6 (6) 0.280 12.6 (38) 15.11 (16) 0.053
omega 6 [%] 27.4 (59) 27.9 (6) 0.629 25.6 (38) 23.41 (16) 0.035
nuts with
omega 3 [%] 13.5 (38) 14.5 (27) 0.230 13.8 (23) 13.2 (30) 0.559
omega 6 [%] 27.8 (38) 26.9 (27) 0.811 24.4 (23) 25.4 (30) 0.361
*based on the t-test
Only significant P values are bold
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foods during the previous week. In short, the FFQ mea-
sures specific details whereas the MEDAS is measuring
for components of an overall dietary pattern. For the
conversion of food intake data from FFQ into MEDAS
food groups only aggregated FFQ data can be used in
most cases. For instance, question 3 on vegetables and
question 4 on fruits each comprised several questions
from FFQ. A further example is that FFQ provides, 3no
information on how many times boiled vegetables, pasta,
rice, or other dishes with a sauce of tomato, garlic,
onion, or leeks sautéed in olive oil are consumed. It asks
only about the consumption of tomato sauce, but no fur-
ther details (e.g. way of cooking or ingredients). Only
question 9 (pulses) which has a high concordance is
based on a direct answer of FFQ. Additionally, in this
study FFQ was completed again within after an interval
of just 3 months, which means that the answers for the
two time points for FFQ in our analysis overlap for a
period of time.
The Bland-Altman analysis showed that the MEDAS
score yields higher values for the sum of all items than
FFQ with respect to MD. This confirms the results of
Schröder et al., who report that the average MEDAS
Mediterranean diet score estimate was 105% of the FFQ
PREDIMED score estimate [11]. The larger difference be-
tween the two score sets after 3 months can be a result of
the MD-based intervention in the IG. The MEDAS
Fig. 2 Association of vegetable consumption (question 3 of the MEDAS questionnaire) and fruit consumption (question 4 of the MEDAS questionnaire)
with β-carotene; and association of fish consumption (question 10 of the MEDAS questionnaire) with omega-6 fatty acids and omega-3 fatty acids after
3 months (V1) [0 = 0 point in the MEDAS question; 1 = 1 point in the MEDAS question]. The p-value was calculated using the t-test
Table 5 Dietary blood biomarkers association with MEDAS food
groups, assessed using multivariate regression
Baseline At 3 months
Dietary biomarker association
with MEDAS food group
Estimate p-Value Estimate p-Value*
β-Carotene with
Fresh vegetables −22 0.197 446 0.104
Fruits 237 0. 287 366 0.147
omega 3 with
Amount of olive oil −0.99 0.415 1.1 0.230
Red meat −0.99 0.282 2.2 0.099
Fish −2.1 0.133 2.1 0.037
Nuts 1.5 0.094 −1.2 0.225
omega 6 with
Amount of olive oil 0.269 0.775 −0.4 0.702
Red meat 0.243 0.734 −1.3 0.360
Fish 0.834 0.433 −2.4 0.026
Nuts −0.96 0.162 1.5 0.147
omega 9 with
Amount of olive oil −0.095 0.114 −0.054 0.542
HsCRP with
Amount of olive oil −0.234 0.402 −0.3 0.161
*adjusted for the study arm
Only significant P values are bold
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questionnaire was specifically developed to detect the ad-
herence of an individual’s diet to the principles of the MD.
Therefore, MEDAS is more sensitive for MD items than
FFQ, resulting in higher scores in individuals abiding by
the MD. The FFQ questions, however, assesses the general
food intake and does not focus particularly on the con-
sumption of Mediterranean food. Two points can be con-
sidered relevant for detecting an adequate implementation
of MD in life.
To confirm if the MEDAS’ tendency towards the MD is
consistent, we analyzed the association between certain
MD food items and selected dietary intake biomarkers in
the blood thought to be associated with these food items.
The traditional MD is characterized by a high intake of
olive oil, fruit, nuts, vegetables, and cereals; a moderate in-
take of fish and poultry; and a low intake of dairy prod-
ucts, red meat, processed meats, and sweets; while wine is
consumed moderately and only together with meals
[1, 23]. In the literature, it is described that a high
consumption of fruits and vegetables is associated with
higher β-carotene blood levels [26]. Kitamura et al. have
previously positively correlated frequency of vegetables
and fruit intake with β-carotene, among other things [26].
In our study, subjects who consumed at least two portions
of vegetables per day according to the MEDAS question-
naire had higher β-carotene blood levels than those who
consumed fewer than two portions at both time points.
Those who consumed at least three portions of fruit per
day according to the MEDAS questionnaire also had
higher β-carotene levels in their blood than those who
consumed fewer than three portions. This data supports
that the MEDAS results reflect the reported intake of par-
ticular nutrients charachterisic of a MD pattern.
The MD is rich in poly- and mono-unsaturated fatty
acids due to the high consumption of olive oil, fish and
nuts [27]. The amount of saturated fatty acids in the
MD is lower than in the Western-style diet, because red
meat and processed meat products play a minor part in
the Mediterranean nutrition. The Western-style diet is
characterized by its highly processed and refined foods
and high contents of sugars, salt and fat and protein
from red meat [28]. Olive oil is characterized by a high
content of mono-unsaturated fatty acids. Oleic acid
(C18:1, n-9) is the main component of olive oil [27].
Therefore, we hypothesized that a high consumption of
olive oil, fish and nuts and low red meat intake are asso-
ciated with changes in the fatty acid profile measured in
erythrocyte membrane. Barcelo et al. described elevated
values of omega-3-fatty acids and low values of omega-
6-fatty acids following high olive oil consumption, while
the omega-9-fatty acid amount remained unchanged
[29]. Our data demonstrated that, more than four table-
spoons of olive oil per day were associated with a ten-
dency to higher serum levels of all unsaturated fatty
acids (omega-6, −3 and −9) compared with the values
measured in subjects who consumed less olive oil. Tak-
kumen et al. described an association between high fish
consumption and a change in the omega-6 and −3-fatty
acids profile. The amount of omega-6-fatty acids de-
creased while that of omega-3-fatty acids increased [30].
At least three portions of fish and seafood per week were
statistically significantly associated with lower omega-6-
fatty acids values (24% compared to 26.3%, p = 0.016)
and higher omega-3-fatty acids values. While high meat
consumption is associated with higher omega-6-fatty
acids values [30], such tendencies could also be seen in
this study.
Barceló et al. [29] also reported an association between
hsCRP values and olive oil consumption. According to
their data, a MD enriched with olive oil (1 litre per week)
resulted in a reduction of the plasma hsCRP concentra-
tion. Such tendencies could also be seen in this study. In-
dividuals who consume more than four tablespoons of
olive oil per day had lower values of hsCRP than individ-
uals who consume less olive oil. The described associa-
tions between certain food items and blood values
indicate that the MEDAS score indeed reflects a MD.
Within this context, MEDAS provides reasonable esti-
mates to adequately rank MD adherence.
Study limitations comprise firstly, a small sample size
meaning the statistical tests would only have small
power. A further limitation of this study is that our find-
ings may not apply to the general population as the par-
ticipants belonged to a selected population who may
have a particular dietary behaviour due to their know-
ledge about their genetic disposition for breast cancer.
We will be using the German MEDAS in our main
trial that aims to recruit 600 study participants. We de-
cided to use the adherence to MD measured by the
MEDAS score as one of 3 co-primary endpoints [31].
Conclusions
Despite the study limitations, we conclude that the present
version of MEDAS could be a reasonable tool in determin-
ing adherence to a MD in German-speaking populations.
This short screener is a valid tool for the rapid assessment
of adherence to the MD that may also be useful not only
for trials but also in clinical practice. The MEDAS score
would allow an immediate feedback to study participants
or patients regarding their adherence to MD.
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The most common cancer among women in Germany – and in the world – is breast cancer, of 
which 5-10% can be attributed to inherited pathogenic variants of certain genes. BRCA1 and 
BRCA2, are two such genes, which act as tumour suppressors and mutations in which are known 
to increase the risk of breast cancer greatly. Current choices for women facing this risk are 
prophylactic surgery or intensive surveillance programmes. 
There are however, non-genetic factors, for instance lifestyle-related, that are known to reduce 
the risk of sporadic breast cancer. Therefore, a clinical trial – LIBRE – was designed to explore 
the effects of some of these lifestyle changes in BRCA1 and BRCA2 germline mutation carriers. 
The trial is multi-centre, randomised, controlled and open-label. The one-year intervention 
consists of endurance sport training and the adoption of the Mediterranean Diet. The 
intervention is divided into two parts, an intensive (first three months) phase and a light phase 
 22 
 
(the following nine months). In this trial two nutritional questionnaires are administered, the 
Food Frequency Questionnaire (FFQ) and Mediterranean Diet Adherence Screener (MEDAS). 
In the publication introduced in this thesis, the German version of MEDAS was validated, 
comparing it to the previously validated German FFQ. The translation and validation of 
MEDAS were done in the setting of the LIBRE study.  
The validation was done in several steps, the first of which was item-level agreement analysis 
by means of absolute agreement, Pearson’s product-moment correlation, Cohen’s kappa and 
intraclass correlation. The Bland-Altman method was used to compare the Mediterranean Diet 
scores resulting from the questionnaires. Then the association of dietary intake biomarkers β-
carotene, fatty acids omega-3, omega-6 and omega-9, and high-sensitivity C-reactive protein 
(hs-CRP) with corresponding MEDAS questions regarding vegetables and fruits, olive oil, red 
meat, fish and nuts was analysed using t-Tests and multivariate linear regressions. All analysis 
was done using data from Baseline and after three months. 
Item-level agreement varied between questions, but was strongest where both questionnaires 
asked the questions similarly, e.g. the question on consumption of olive oil and nuts in general. 
On the other hand, the lowest agreement was seen where the MEDAS question was asked 
indirectly in FFQ, e.g. the question on daily portions of olive oil. The Bland-Altman analysis 
showed that mean Mediterranean Diet scores resulting from MEDAS were 15% higher than the 
scores from FFQ at baseline and 23% higher after three months. This meant that MEDAS is 
more sensitive to (has a bias) towards MD items in comparison to the FFQ. 
Additionally, significant associations between dietary biomarkers in the blood and specific MD 
food groups (questions from MEDAS) were found. Consumption of more fish, i.e. at least 3 
portions a week was associated with higher omega-3 and lower omega-6 fatty acids. More fruit 
and vegetable consumption showed an association with higher levels of β-carotene. In the 
analysis of the association of several food items together with dietary intake biomarkers, higher 
fish consumption again showed a significant association with higher omega-3 and lower omega-
6 fatty acids. 
In conclusion, the satisfactory agreement of MEDAS and FFQ, and the higher sensitivity of 
MEDAS to the MD speak for its suitability to measure adherence to the MD. Additionally, 
despite the low participant numbers and thus small statistical power, associations between 
MEDAS and relevant dietary intake biomarkers in the blood were found. This speaks for the 
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suitability of this translation of the MEDAS in determining the adherence to the MD in German-
speaking populations. 
The MEDAS German version as presented here is being used in the LIBRE-2 study. It is going 
to be used for another project, ENDORE, focusing on female infertility. The ENDORE project 
will run 2018 – 2021 with centres in Spain, Sweden, Estonia, Germany and USA. The German 
version will also be used in yet another project, the LIFE-Heart Follow-up study in Leipzig, 
which will run from 2018. 
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MEDAS 
Mediterranean Diet Adherence Screener – Fragebogen zur Mediterranen Kost 
 
Übersetzt von ©Institut für Ernährungsmedizin, Universität Hohenheim, Stuttgart im Rahmen der 
LIBRE-Machbarkeitsstudie (Lebensstilintervention bei gesunden und erkrankten BRCA1/2 
Mutationsträgerinnen und Frauen mit einem hohen Risiko für Brust- und Eierstockkrebs- 
Prospektive randomisierte multizentrische Feasibility-Studie) 
 
Englische Originalversion: Schröder et al., J Nutr. 2011 Jun;141(6):1140-5. 
 
Deutsche Validierung: Hebestreit et al., BMC Cancer. 2017 May 18;17(1):341. 
 
Bitte beachten Sie: 
 
1. Eine Haftung des Instituts für Ernährungsmedizin im Zusammenhang mit der Nutzung des 
Fragebogens ist ausgeschlossen.  
 
2. Bei Publikationen, die sich auf Daten oder Informationen beziehen, die mit Hilfe dieses 
Fragebogens generiert wurden, ist auf die LIBRE-Studie, das Institut für Ernährungsmedizin an der 
Universität Hohenheim (z.B. „Acknowledgment“) sowie die o.g. Validierungsstudie hinzuweisen.  
 
3. Der Fragebogen darf nicht an Dritte weitergegeben werden. 
 
Auswertung: 
Jede Frage wird mit 1 oder 0 Punkten bewertet. Die Antworten der linken Spalte werden mit einem 
Punkt gerechnet, die Antworten der rechten Spalte mit 0 Punkten. Anschließend wird die 
Gesamtsumme aller Fragen gebildet. Bitte beachten Sie, dass der Fragebogen nicht berücksichtigt, ob 
sich jemand vegetarisch ernährt. Falls deshalb Fragen ausgelassen werden, kann das Ergebnis auch 
prozentual angegeben werden.  
  
Prof. Dr. Stephan C. Bischoff 
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1 Verwenden Sie in der Küche hauptsächlich Olivenöl? ja  nein  
  
 
2 Wie viel Olivenöl konsumieren Sie insgesamt am Tag 
(einschließlich dem Gebrauch zum Braten, zur 
Zubereitung von Salaten und Mahlzeiten und bei 
Restaurantbesuchen)? 
mind. 4 
Esslöffel 
 weniger als 4 
Esslöffel 
 
  
  
  
  
3 Wie viele Portionen frisches Gemüse (z.B. Eisbergsalat 
oder Spinat) konsumieren Sie pro Tag?  
 
 
 
 
mind. 2 
(davon 1 als 
Salat od. in 
Form von 
Rohkost) 
 weniger als 2   
  
  
  
  
 
4 Wie viele Portionen Obst (einschließlich Fruchtsäfte) 
konsumieren Sie pro Tag? 
mind. 3  weniger als 3  
  
 
 
 
 
5 Wie viele Portionen rotes Fleisch, Hamburger, Wurst 
bzw. Wurstaufschnitte konsumieren Sie pro Tag? 
weniger als 1  mind. 1  
  
 
 
 
6 Wie viele Portionen Butter, Margarine oder Sahne 
konsumieren Sie pro Tag? 
weniger als 1  mind. 1  
  
  
      
7 Wie viele Portionen zuckerhaltige Getränke 
(Erfrischungsgetränke, Cola, Energydrinks, Eistee, 
Bionade, etc.) konsumieren Sie pro Tag? 
weniger als 1  mind. 1  
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8 Wie viel Wein konsumieren Sie pro Woche? mind. 7 Gläser  weniger als 7 
Gläser 
 
  
  
 
9 Wie viele Portionen Hülsenfrüchte (z.B. Bohnen, 
Erbsen, Linsen) konsumieren Sie pro Woche? 
 
 
mind. 3   weniger als 3  
  
  
 
10 Wie viele Portionen Fisch oder Meeresfrüchte 
konsumieren Sie pro Woche? 
mind. 3  weniger als 3  
  
  
 
11 Wie viele Portionen Süßigkeiten (z.B. Schokolade, 
Bonbons, Gummibärchen) oder fertige (nicht 
selbstgebackene) Back - und Süßwaren wie Kuchen, 
Plätzchen, Kekse oder Pudding konsumieren Sie pro 
Woche? 
weniger als 3  mind. 3  
  
 
 
  
  
 
12 Wie viele Portionen Nüsse (einschließlich Erdnüsse) 
konsumieren Sie pro Woche? 
 
 
mind. 3  weniger als 3  
  
  
 
13 Bevorzugen Sie Hähnchen, Pute oder Kaninchen vor 
Rind, Schwein, Hamburger oder Wurstwaren? 
ja  nein  
  
 
14 Wie oft pro Woche konsumieren Sie Nudeln, Reis, 
Gemüse oder andere Gerichte, die mit einer Sauce aus 
Tomaten, Knoblauch, Zwiebeln oder Lauch, und mit  
Olivenöl zubereitet wurden? 
mind. 2 Mal  weniger als  
2 Mal 
 
  
  
  
 Gesamtpunktzahl  
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